DermaRite Industries Initiates Class II Recall of McKesson Skin Protectant Due to CGMP Deviations and Contamination
DermaRite Industries, LLC has initiated a Class II recall for McKesson Skin Protectant, Lanolin USP, citing Current Good Manufacturing Practice (CGMP) deviations. Products manufactured at its North Bergen, NJ facility were found to be contaminated, posing a significant risk to supply chains. Procurement and regulatory teams must assess immediate inventory impacts and re-evaluate supplier quality oversight.
FDA Initiates Class II Recall for DermaRite's McKesson Skin Protectant
DermaRite Industries, LLC, based in North Bergen, NJ, initiated a voluntary Class II recall (D-0171-2026) on August 27, 2025, for McKesson Skin Protectant, Lanolin USP. This critical action was prompted by significant Current Good Manufacturing Practice (CGMP) deviations at DermaRite's manufacturing facility located at 7777 W Side Ave, North Bergen, NJ 07047-6436. Crucially, the recall reason specifies that these products were manufactured at a facility where other product lots were also found to be contaminated, indicating a systemic quality control issue rather than an isolated incident. The affected products include McKesson Skin Protectant, Lanolin USP, packaged in 5g (NDC 68599-6202-1) and 4oz (NDC 68599-6203-4) tubes, distributed by McKesson Medical-Surgical Inc., Richmond, VA 23233. All lots with an expiry date on or before August 2027 are within the scope of this recall. For procurement directors, this necessitates an immediate audit of existing inventory and supply contracts for all Lanolin USP-based skin protectants, particularly those sourced from DermaRite or distributed by McKesson. Regulatory affairs heads must initiate a thorough review of their third-party manufacturing oversight protocols, placing a strong emphasis on facilities with a documented history of broader contamination issues. The Class II classification, signifying a potential for temporary or medically reversible adverse health consequences, demands a swift and decisive business response.
Supply Chain Vulnerabilities: Impact on Lanolin USP Distribution
The recall encompasses 5,876 units of McKesson Skin Protectant, Lanolin USP, a volume that, while not globally massive, represents a notable disruption within McKesson Medical-Surgical Inc.'s nationwide USA distribution network. Lanolin USP, identified by its generic name Lanolin (RXCUI 1038957, UNII 7EV65EAW6H), is a widely utilized emollient in topical human OTC drugs. Its commonality means this recall can significantly impact healthcare facilities, pharmacies, and consumers who depend on these products for essential skin protection. The broad distribution pattern across the United States amplifies the potential for localized shortages and necessitates a rapid response from supply chain stakeholders. Supply chain VPs must quantify the immediate and projected impact of removing these 5,876 units from circulation. This requires the urgent identification and qualification of alternative sources for Lanolin USP-based products to prevent stockouts and maintain continuity of care or retail availability. Business development executives should actively assess market gaps created by this recall, particularly within the topical drug segment, to strategically position their compliant alternative offerings. The "Ongoing" status of this recall mandates continuous vigilance and proactive management of inventory and supplier relationships to mitigate further risks.
Addressing Systemic Quality Control and Contamination Risks
The FDA's action, driven by "CGMP Deviation" and the discovery that "other products and lots were found to be contaminated" at DermaRite's North Bergen, NJ facility, points to a critical failure in maintaining Current Good Manufacturing Practices. These practices are fundamental to ensuring drug quality, safety, and efficacy. The pervasive nature of the contamination across multiple products and lots suggests a systemic breakdown in environmental control, raw material handling, sanitation procedures, or overall quality management systems. Such systemic failures often trigger heightened scrutiny from the FDA, potentially extending to other products manufactured at the facility, even those not directly implicated in this specific recall. While DermaRite initiated this recall voluntarily, acknowledging the deviation, the underlying issues demand comprehensive and robust remediation. Regulatory affairs heads must ensure their internal and external audit programs are sufficiently rigorous to detect such systemic CGMP deviations, particularly when engaging contract manufacturing organizations (CMOs). Procurement teams must evolve beyond basic quality checks, implementing comprehensive facility audits that evaluate overall contamination control strategies and the robustness of quality management systems. Failure to proactively address these systemic risks can lead to further recalls, severe reputational damage, and substantial financial penalties, underscoring the critical liabilities associated with inadequate supplier oversight.
Proactive Mitigation and Future Sourcing Strategies for Lanolin USP
Given the "Ongoing" status of the recall and the underlying systemic CGMP deviations, companies must adopt a highly proactive and strategic stance. The recall initiation date of August 27, 2025, followed by the report date of November 26, 2025, indicates a sustained regulatory process that will require ongoing attention. Procurement directors should immediately map their entire supply chain for Lanolin USP and similar topical drug excipients or active pharmaceutical ingredients. This mapping is crucial for identifying single points of failure and prioritizing the qualification of geographically diverse alternative suppliers. While the ChemLifeIntel Knowledge Graph does not provide specific alternative suppliers for DermaRite, the market for Lanolin USP is competitive, and diligent market research can identify new, compliant partners. Supply chain VPs need to develop robust contingency plans, including strategies for buffer stock and multi-sourcing initiatives, to build resilience against future disruptions stemming from regulatory actions. Business development executives can leverage this event to highlight their company's robust quality systems and compliant manufacturing capabilities to potential new clients who may be impacted by this recall. Regulatory affairs teams should utilize this incident as an opportunity to reinforce internal training on CGMP compliance and conduct mock audits to strengthen their readiness for future FDA inspections. This proactive, multi-faceted approach is essential for maintaining market continuity, ensuring product quality, and upholding regulatory compliance.